All In Biotech

NDA 022532 · Bayer Hlthcare

Beyaz

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium · Oral

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Sep 24, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

1,626

772 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Beyaz. ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 ) WARNING TO WOMEN WHO SMOKE Do not use Beyaz if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and...

What it is approved for

From the label in effect Mar 2, 2026.

Beyaz is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.4 ) 1.1 Oral Contraceptive Beyaz ® is indicated for use by females of reproductive potential to prevent pregnancy. 1.2 Premenstrual Dysphoric Disorder (PMDD) Beyaz is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in females of reproductive potential who choose to use an oral contraceptive as their method of contraception. The effectiveness of Beyaz for PMDD when used for more than three menstrual cycles has not been evaluated. The essential features of PMDD according to the Diagnostic and Statistical Manual-4th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school,...

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BEYAZ · DROSPIRENONE 3MG,N/A; ETHINYL ESTRADIOL 0.02MG,N/A; LEVOMEFOLATE CALCIUM 0.451MG,0.451MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pulmonary embolism310
  • deep vein thrombosis243
  • injury236
  • pain205
  • emotional distress163
  • anxiety148
  • drug dose omission97
  • no adverse event97
  • general physical health deterioration93
  • anhedonia84
  • metrorrhagia76
  • nausea69

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
2011332
2012457
2013360
2014164
201595
201683
201737
201824
201911
202018
202117
20225
20239
20244
20255
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Beyaz (Drospir/Eth Estra/Levomefol Ca)

2024 spending

$22K

Beneficiaries

n/a

34 claims

Per beneficiary

n/a

$8.17 per unit

View as table
YearSpending
2020$37,620
2021$32,873
2022$40,307
2023$31,516
2024$21,950

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 311 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.